Glioblastoma is an aggressive incurable primary tumor of the central nervous system. Median overall survival is in the range of 1.5 years even in selected clinical trials populations. Many features contribute to this therapeutic challenge including high intratumoral and intertumoral heterogeneity, resistance to therapy, migration and invasion, immunosuppression. With the access of novel highthroughput technologies, significant progress has been made to understand molecular and immunological signatures underlying the pathology of glioblastoma. Clinical trial designs have shifted from investigating broad “one-for-all” treatment approaches to precision oncology designs. The collection of contributions in this book aim at providing researchers and clinicians an update on different aspects of glioblastoma, i.e. progress in basic, preclinical and clinical research.

Glioblastoma is an aggressive incurable primary tumor of the central nervous system. Median overall survival is in the range of 1.5 years even in selected clinical trials populations. Many features contribute to this therapeutic challenge including high intratumoral and intertumoral heterogeneity, resistance to therapy, migration and invasion, immunosuppression. With the access of novel highthroughput technologies, significant progress has been made to understand molecular and immunological signatures underlying the pathology of glioblastoma. Clinical trial designs have shifted from investigating broad “one-for-all” treatment approaches to precision oncology designs. The collection of contributions in this book aim at providing researchers and clinicians an update on different aspects of glioblastoma, i.e. progress in basic, preclinical and clinical research.

Treatment of malignant glioma remains a major challenge for neurosurgeons, neurologists, medical oncologists, and radiation oncologists caring for patients with these tumors. Glioblastoma multiforme, the most common type of brain tumor, is also the most deadly -- only five percent of patients or fewer will be alive at five years after diagnosis. This comprehensive new reference is edited by a renowned team consisting of a neurosurgeon, medical oncologist, oncologic surgeon, and radiation oncologist. The book provides basic researchers and clinicians with a contemporary review of the epidemiology, diagnosis, and treatment of glioblastoma multiforme, and also imparts to experienced investigators outside of the field sufficient background to apply their skills to the treatment of this deadly disease. Expert malignant glioma researchers and clinicians provide state-of-the-art chapters on important topics such as molecular genetic classification of glioblastoma, surgical management, stem cell therapy, chemotherapy, angiogenesis, and more.

This book is a compilation of articles that brings together current knowledge from an international team of contributors who are dedicated investigators exploring novel strategies for the treatment of glioblastoma. These articles describe some of the latest concepts that will provide students, researchers and clinicians with an overview of the therapeutic approaches being developed in the field of neuro-oncology to combat this deadly disease.

Non-thermal irreversible electroporation is a new minimally invasive surgical p- cedure with unique molecular selectivity attributes – in fact it may be considered the first clinical molecular surgery procedure. Non-thermal irreversible electro- ration is a molecular selective mode of cell ablation that employs brief electrical fields to produce nanoscale defects in the cell membrane, which can lead to cell death, without an effect on any of the other tissue molecules. The electrical fields can be produced through contact by insertion of electrode needles around the undesirable tissue and non-invasively by electromagnetic induction. This new - dition to the medical armamentarium requires the active involvement and is of interest to clinical physicians, medical researchers, mechanical engineers, che- cal engineers, electrical engineers, instrumentation designers, medical companies and many other fields and disciplines that were never exposed in their training to irreversible electroporation or to a similar concept. This edited book is designed to be a comprehensive introduction to the field of irreversible electroporation to those that were not exposed or trained in the field before and can also serve as a reference manual. Irreversible electroporation is broad and interdisciplinary. Therefore, we have made an attempt to cover every one of the various aspects of the field from an introductory basic level to state of the art.

This volume provides a balanced and realistic review of the current state of glioblastoma, ranging from traditional histological review, molecular pathology of glioma, modern radiomics, neurosurgical focus, and integration of treatment plans by neuro-oncologists. The book reviews basic principles such as epidemiology and etiology, and modern 2016 WHO classification of CNS tumors. Chapters cover a general overview of common molecular techniques used in molecular pathology, molecular pathology in a developing country, key drivers of patient outcomes and predictors of response to radiation and/or chemotherapy treatment, and immunohistochemical surrogates for key molecular pathology. It concludes with reviews on radiomics, animal and stem cell models of glioblastoma, and a chapter on the emerging field of Glioblastoma Neuroscience. Precision Molecular Pathology of Glioblastoma is intended for pathology residents and fellows interested in glioblastoma, general surgical pathologists who need reviews on how to implement modern glioblastoma classification, as well as neuro-radiologists, oncologists, and radiation oncologists needing a holistic perspective to glioblastoma diagnosis and management.